Evidence against an increase in capillary permeability in subjects exposed to high altitude. J. Appl. Physiol. 81(5): 1917-1923.-A potential pathogenetic cofactor for the development of acute mountain sickness and high-altitude pulmonary edema is an increase in capillary permeability, which could occur as a result of an inflammatory reaction and/or free radical-mediated injury to the lung. We measured the systemic albumin escape by intravenously injecting 5 µCi of 125 I-labeled albumin and the plasma concentrations of cytokines, F 2 -isoprostanes (products of lipid peroxidation), and acute-phase proteins in 24 subjects exposed to 4,559 m. Ten subjects developed acute mountain sickness, and four subjects developed high-altitude pulmonary edema. The transcapillary escape rate of albumin was 6.9 6 2.0%/h (SD) at low (550 m) and 6.3 6 1.9%/h at high (4,559 m) altitude (P 5 0.23; n 5 24). The subjects with high-altitude pulmonary edema had a modest but insignificant increase in the transcapillary escape rate of albumin (4.6 6 1.9%/h at low vs. 5.7 6 1.9%/h at high altitude; P 5 0.42; n 5 4). Plasma concentrations of fibrinogen, a 1 -acid glycoprotein, C-reactive protein, and interleukin-6 were unchanged in the early phases and significantly increased by the end of the observation period in the subjects with high-altitude pulmonary edema, whereas tumor necrosis factor-a and F 2 -isoprostanes did not change at all. This suggests that the inflammatory reaction was rather a consequence than a causative factor of high-altitude pulmonary edema. In summary, these data argue against a dominant role for increased systemic capillary permeability in the development of acute mountain sickness and high-altitude pulmonary edema. vascular permeability; high-altitude pulmonary edema; acute mountain sickness; free radicals; F 2 -isoprostanes HIGH-ALTITUDE PULMONARY EDEMA (HAPE) is a noncardiogenic pulmonary edema that may occur during the first days of acute exposure to high altitude (19). HAPE is associated with an increase in leakage of both fluid and proteins into the alveolar space (34, 35) and enhanced hypoxic pulmonary vasoconstriction (20). It is not clear, however, whether the increased leakage of fluid and proteins is a cause or a consequence of HAPE. In contrast, a causative role for high pulmonary arterial pressure in the development of HAPE has been suggested by many workers. In this regard, pulmonary arterial hypertension has been shown to precede HAPE formation (5), and lowering pulmonary arterial pressure by various drugs is associated with short-term improvement of pulmonary gas exchange (15, 33), long-term clinical improvement (29), and prevention of HAPE (5).
HIGH-ALTITUDE PULMONARY EDEMA (HAPE) is a noncardiogenic pulmonary edema that may occur during the first days of acute exposure to high altitude (19) . HAPE is associated with an increase in leakage of both fluid and proteins into the alveolar space (34, 35) and enhanced hypoxic pulmonary vasoconstriction (20) . It is not clear, however, whether the increased leakage of fluid and proteins is a cause or a consequence of HAPE. In contrast, a causative role for high pulmonary arterial pressure in the development of HAPE has been suggested by many workers. In this regard, pulmonary arterial hypertension has been shown to precede HAPE formation (5) , and lowering pulmonary arterial pressure by various drugs is associated with short-term improvement of pulmonary gas exchange (15, 33) , long-term clinical improvement (29) , and prevention of HAPE (5) .
The transcapillary escape rate (TER) of albumin is a measure of the systemic capillary permeability (1, 2, 30) and was reported to be elevated in subjects exposed to high altitude irrespective of the presence of acute mountain sickness (AMS) or HAPE (8, 16) . Coates et al. (8) demonstrated a modest but insignificant increase in the TER in healthy subjects exposed to an altitude of 4,300 m in a pressure chamber. In a recent study, Hansen et al. (16) measured the TER in healthy volunteers flown to 4,350 m and reported a significant increase in the TER.
Previous studies that investigated the influence of high altitude on the TER did not include subjects susceptible to HAPE and did not explore potential pathogenetic factors (e.g., various inflammatory cytokines and free radical mediated-injury) that could cause an increase in systemic capillary permeability (3, 11, 12, 23, 25) . We were particularly interested in exploring the hypothesis that free radical injury to the lung may play a role in the development of HAPE. This was based on the fact that a release of tumor necrosis factor (TNF) can occur in settings of diminished tissue oxygenation and that TNF can cause enhanced hypoxic pulmonary vasoconstriction, generation of free radicals, and pulmonary edema (9, 14, 21, 22, 32) . We investigated this hypothesis by determining whether exposure to high altitude caused an increase in TNF release and F 2 -isoprostane formation. F 2 -isoprostanes are prostaglandin-like products of lipid peroxidation, and quantification of F 2 -isoprostanes has proven to be a reliable and sensitive marker of free radical-mediated injury in vivo (26) (27) (28) . We therefore investigated whether high-altitude exposure in HAPE-resistant and HAPE-susceptible subjects was associated with an increase in TER, altered levels of acute-phase proteins and various plasma cytokines, or enhanced formation of F 2 -isoprostanes, an indicator of free radical-mediated injury.
METHODS
Subjects and study design. Twenty-four healthy subjects with former exposure to high altitude (.4,000 m) were prospectively studied. Eight of the subjects had a history of at least one documented episode of HAPE, and two had a history of AMS. All subjects were studied in the metabolic unit of the University Hospital of Bern, Switzerland (550 m; baseline) and 3-4 wk later at a mountain hut in the Swiss-Italian Alps (Capanna Margherita, 4,559 m). They started their active ascent on foot at an altitude of 3,200 m and reached 3,611 m on the first day. After an overnight stay, they continued the ascent to 4,559 m and remained at this altitude for ,40 h, which included two overnight stays.
The clinical investigations and determinations of the plasma concentrations of various cytokines, acute-phase proteins, and F 2 -isoprostanes were performed at baseline (i.e., time point pre-ascent), within 2-3 h after arrival at 4,559 m (time point HA-1d), in the morning after the first night (time point HA-2d), and after the second night at 4,559 m before departure (time point HA-3d). The TER was measured at time points pre-ascent and HA-2d, and chest radiography was performed at time points pre-ascent and HA-3d or when clinical signs of HAPE were present.
The study protocol was approved by the Ethical Committee of the University of Bern, and written informed consent was obtained from the subjects before they participated in the study.
Measurement of TER of albumin. The TER was measured according to the method described previously (1-3). The subjects received 60 mg of potassium iodide orally starting the day before the investigation and for 14 days thereafter to block 125 I uptake by the thyroid gland. After an overnight fast, 5 µCi of 125 I-labeled albumin (Sari-125-A-2, Sorin Biomedica, Saluggia, Italy) were injected intravenously, and blood samples were drawn from an opposite cubital vein at 10-min intervals over a period of 60 min. Radioactivity was counted in 2-ml plasma samples on a gamma counter (1260 Multigamma II, Wallac, Turku, Finland) and expressed as counts per minute. Usually, albumin escape is expressed as a monoexponential function because albumin molecules escape from the intravascular compartment proportionally to the plasma albumin. However, the linear and monoexponential curves of the decrease in counts over the first 60 min after an intravenous injection were not different, as described earlier (1) . Therefore, the TER of albumin was calculated from the linear regression line of the decrease in plasma radioactivity over 60 min, according to the formula (1, 3, 31) TER (in %/h) 5 (a 3 60 3 100)/y, where a is the slope and y is the intercept of the linear regression.
Determination of plasma protein concentrations. Plasma protein concentrations were measured at all time points (i.e., pre-ascent to HA-3d). Plasma albumin concentration was determined with bromcresol purple (10) on a Hitachi 717 autoanalyzer (Wako Pure Chemical Industries, Osaka, Japan); transferrin, a 1 -acid glycoprotein, and prealbumin were determined by nephelometry (Behring, Marburg, Germany); and C-reactive protein (CRP) was determined by turbidimetry. Plasma fibrinogen concentration was measured according to the method of Clauss (7) .
Determination of plasma cytokine concentrations. Interleukin (IL)-6, IL-1b, IL-2, soluble IL-2 receptor, TNF-a, and TNF-a receptor P-60 plasma concentrations were measured with commercial assays (Quantikine, RD Research and Diagnostics System, Minneapolis, MN).
Measurement of F 2 -isoprostanes. Plasma concentrations of F 2 -isoprostanes were measured by stable-isotope dilution mass spectrometric assay (27) . The precision of the assay is 66%, and the accuracy is 96%.
Other determinations. Arterial blood gas analyses were performed in samples drawn from a radial artery by a microsampler (Biomedical, Industrade, Graz, Austria) on a blood gas system (Ciba Corning Diagnostics, Dietlikon, Switzerland).
The degree of AMS was determined by the Lake Louise score by the same interviewer at all time points (6). AMS was diagnosed when the Lake Louise score was .5. Chest radiographs were performed at pre-ascent and at day HA-3d or when the clinical assessment and/or the analysis of the blood gases indicated HAPE by a mobile X-ray unit (TRS, Siemens, Stockholm, Sweden) with a fixed target-to-film distance of 1.4 m at 133 kV and 4-6 mAs. The diagnosis of HAPE was confirmed as described previously (37) .
Statistical analyses. The data are expressed as means 6 SD. Differences among the groups and different time points were calculated by means of nonparametric tests, assuming a significance level of P # 0.05.
RESULTS

Clinical examinations.
Fourteen of the twenty-four subjects (58%) suffered from AMS and four developed HAPE (17%). The AMS scores of all subjects are summarized in Table 1 . HAPE was diagnosed on day HA-2d in one subject and on day HA-3d in the other three. Two of the subjects with AMS departed after the determinations at time point HA-2d because of progressive symptoms of mountain sickness.
Three subjects with AMS received dexamethasone after and one before the determination of the TER. They were included in the final calculation because omitting them did not change the results. All subjects with HAPE showed a rapid improvement of symptoms after treatment with supplemental oxygen and oral nifedipine (20 mg every 6 h). For safety reasons, the two subjects with the most severe HAPE were flown out by helicopter to 1,600 m where they recovered completely within a few hours.
In Table 2 , the results of the arterial blood gas analyses are summarized in the three groups, i.e., in subjects without AMS or HAPE (AMS/HAPE), with AMS, and with HAPE.
TERs and plasma concentrations of albumin. Figure  1 shows a typical curve of the decline in plasma radioactivity, demonstrating the linear decrease over the first 60 min (1). In Fig. 2 , the TERs of albumin are shown for the three groups. The TER was 6.9 6 2.0%/h at low and 6.3 6 1.9%/h at high altitude in all subjects (P 5 0.23; n 5 24). TER was 7.5 6 1.2 and 7.1 6 1.8%/h (P 5 0.61) in the group without AMS/HAPE and 7.3 6 2.2 and 5.8 6 1.9%/h (P 5 0.07) in the group with AMS. The subjects suffering from HAPE showed a modest Values are means 6 SD; n 5 10 subjects/group without acute mountain sickness (AMS)/high-altitude pulmonary edema (HAPE) and with AMS and 4 subjects with HAPE. Pre-ascent, before ascent to high altitude; HA-1d, within 2-3 h of arrival at high altitude; HA-2d, in morning after 1st night at high altitude; HA-3d, after 2nd night at high altitude before departure. A score .5 is indicative of AMS. P values designate differences at a given time point among the 3 groups.
increase in TER (from 4.6 6 1.9 to 5.7 6 1.9%/h), but this difference was not significant (P 5 0.42). When the albumin escape was expressed as an absolute albumin outflux (in g/h or mg · kg body weight 21 ·h 21 ), again there was a modest but insignificant increase in the subjects with HAPE (5.47 6 2.2 to 6.95 6 3.24 g/h; P 5 0.43).
Plasma albumin concentrations were within the normal range and showed no change over time among the three groups (data not shown). The degree of AMS as demonstrated by the Lake Louise score on day HA-2d did not correlate with the values of TER (Fig. 3) .
Plasma protein and cytokine concentrations. The time courses of changes in plasma fibrinogen and a 1 -acid glycoprotein concentrations are given in Table   3 . Fibrinogen (P values are given in Table 3 ) and a 1 -acid glycoprotein plasma concentrations increased significantly in the HAPE subjects at time point HA-3d but did not increase in the other subjects.
In Table 4 , the plasma concentrations of prealbumin and transferrin are summarized. The slight decrease in the plasma concentration of the two proteins was not significant. Figure 4 summarizes the relationship between the time courses of the plasma concentrations of both IL-6 and CRP. Subjects without AMS/HAPE and with AMS showed no significant changes in the plasma concentrations of IL-6 and CRP. In contrast, subjects with HAPE exhibited a significant increase in plasma concentrations of IL-6 at time point HA-2d and of both IL-6 and CRP at time point HA-3d (Fig. 4) .
The plasma concentrations of IL-1b, soluble IL-2 receptor, and TNF-a receptor P-60 exhibited a wide scatter without any significant changes among the groups or at the different time points. IL-2 plasma concentrations were below the level of detection. In contrast, mean TNF-a plasma concentrations were unexpectedly high at baseline in the subjects without AMS/HAPE (see Table 5 ). However, this can be attributed to the fact that two subjects had sustained plasma concentrations that were above normal throughout the entire observation period. Differences at high altitude among the groups were, however, not significant after correction for baseline values by analyzing differences between measurements obtained at baseline and high altitude.
Plasma concentrations of F 2 -isoprostanes. No significant differences in circulating concentrations of F 2 -isoprostanes were observed among groups or at different time points within groups (Table 6) .
DISCUSSION
In the present study, exposure to 4,559 m had no apparent effect on systemic capillary permeability irrespective of AMS. Subjects with HAPE exhibited a slight, albeit nonsignificant, increase in TER. The observed acute-phase reaction in HAPE subjects, reflected by an increase in the plasma concentrations of IL-6 and CRP, is most likely a consequence rather than a cause of HAPE because it occurred at a time point after the subjects had developed HAPE.
In contrast to earlier studies (8, 16), we have not found an increase in the TER of albumin measured by intravenously injecting radiolabeled albumin into the 24 subjects exposed to 4,559 m. Whereas the average TER of subjects without AMS/HAPE and those with AMS remained virtually unchanged, the small number of subjects (n 5 4) who developed HAPE exhibited a modest increase in TER, but this was not significant. In a recent study, Hansen et al. (16) demonstrated a small increase in TER in subjects flown to an altitude of 4,350 m. The values of TER in their subjects, however, were relatively low at sea level (4.8%/h) and increased to only 6.7%/h at high altitude. The latter value would still be close to the normal range of values of TER that Ballmer and colleagues (1, 2) and Parving and Gyntelberg (30) 2 . P values designate differences at a given time point between the 3 groups. Overall, there were highly significant differences between time points pre-ascent and HA-1d to HA-2d in all 3 groups (P , 0.01). have reported. The power analysis in our study indicated a statistical power . 95%, assuming an absolute increase in TER by 2.5%/h (e.g., from 5 to 7.5%/h) and an a error of 5%. Taking sample size and variability into account, this calculation suggests that the increase in TER observed by Hansen et al. (16) might be due to an a error because they examined only 12 subjects, of whom 3 were excluded from the final analysis. Moreover, Hansen et al. compared subjects treated with either a placebo or a calcium-channel blocker (i.e., isradipine). Interestingly, four of the six subjects on the calciumchannel blocker treatment exhibited an increase in TER, whereas only two of the subjects on the placebo showed an increase in TER. Although clearly speculative, one might argue that isradipine itself had an influence on TER. Because calcium-channel blockers are known to give rise to edema formation (24), presumably by causing an increase in systemic vascular permeability, this might well produce an increase in TER.
In the present study, three of the four subjects suffering from HAPE showed small insignificant increases in the TER of albumin (see Fig. 2 ). In the fourth subject in whom the TER did not increase, clear radiographic evidence of beginning HAPE was present Fig. 2 . Values of transcapillary escape rate (TER) of albumin in the 3 groups of subjects exposed to 4,559 m. AMS, acute mountain sickness; HAPE, high-altitude pulmonary edema; Pre-ascent, before ascent to high altitude; HA-2d, in morning after 1st night at high altitude. Subjects suffering from HAPE exhibited a moderate, albeit nonsignificant, increase in TER, whereas all other subjects showed no change. Fig. 3 . TER of albumin showed no correlation with degree of AMS as determined by Lake Louise (LL) score obtained at time point HA-2d when TER was measured. Values are means 6 SD; n 5 10 subjects/group without AMS/HAPE and with AMS and 4 subjects with HAPE. There was a significant increase in fibrinogen and a 1 -acid glycoprotein concentration at HA-3d that was due to elevated levels in HAPE subjects. when the last measurement of TER was obtained. This may suggest that increased capillary permeability is not an essential requirement for the development of HAPE. However, measurement of TER is only a reflection of global capillary permeability and cannot mirror organ-specific changes. Moreover, the lymphatic return may redistribute substantial amounts of extravasated 125 I-labeled albumin very rapidly. Also, the evidence of the present data is limited by the small number of subjects studied. With a larger number of subjects and more precise methods, e.g., early bronchoalveolar lavage, a minute capillary leak in the lungs might have been detected. Nevertheless, the observation in one subject with HAPE and unchanged TER would mitigate against a dominant causative role for increased capillary permeability in the pathogenesis of HAPE.
A potential shortcoming of the present study might be the overall limited sensitivity of the method used for measuring capillary permeability. Comparisons with the previous investigations by Ballmer and colleagues (1, 2) and Parving and Gyntelberg (30) demonstrate somewhat higher values of TER in the present study, with a larger scatter of data that can be attributed to unexpected and unexplained higher values in women (8.3 6 2.0 vs. 6.3 6 1.7%/h in men; P 5 0.02) and possibly the younger age of the present subjects (average age 10 yr lower). Variability of TER data was similar at both altitudes, and the interindividual coefficient of variation in repeated measurements over a few hours was shown by Rossing et al. (31) to be 8.5% and over 1 yr only 14%. For these reasons and because several studies using the same method were able to demonstrate increases in TER, e.g., by .50% after injecting recombinant human IL-2 into melanoma patients (3) or by even 100% within a few hours of cardiac surgery or 300% in patients with septic shock (13), we do not think that methodological problems are responsible for the present negative findings. As pointed out before, a minor generalized capillary leak, however, cannot be excluded with our data.
Our data, which do not support a hypothesis that exposure to hypobaric hypoxia causes an increase in systemic TER, are in accordance with various in vivo findings in the literature. Homik et al. (18) investigated the differential effects of hypoxia and microvascular pressure in an in vivo preparation of dog lungs and demonstrated unequivocally that an increase in microvascular pressure was the only important pathogenetic factor causing edema formation in that model, irrespective of the inspired oxygen concentration. Moreover, Henriksen and Kok-Jensen (17) investigated patients with low oxygen tensions due to chronic obstructive pulmonary disease and found identical values of TER when compared with healthy subjects. On the other Values are means 6 SD in pg/ml; n 5 10 subjects/group without AMS/HAPE and with AMS and 4 subjects with HAPE. No significant changes occurred. Fig. 4 . Plasma concentrations of C-reactive protein (CRP; s) and interleukin-6 (IL-6; r). HA-1d, within 2-3 h after arrival at high altitude; HA-3d, after 2nd night at high altitude before departure. No changes occurred in subjects without AMS/HAPE or with AMS. In contrast, subjects with HAPE showed a significant increase in IL-6 at time point HA-2d, succeeded by a significant increase in both IL-6 and CRP plasma concentrations at time point HA-3d. Values are means 6 SD in pg/ml; n 5 10 subjects/group without AMS/HAPE and with AMS and 4 subjects with HAPE. Tumor necrosis factor-a (TNF-a) plasma concentrations were significantly higher in subjects without AMS/HAPE, but this difference was not significant when statistical analysis was performed correcting for baseline values (see text).
hand, there is evidence from animal studies that both normo-and hypobaric hypoxia increase pulmonary transvascular protein leakage (36) . Thus rats exposed to a barometric pressure resembling 14,500 feet or to a fractional inspired oxygen concentration of 15% exhibited significant increases in protein leakage as measured by tagged albumin. The discrepancies between those findings and ours remain unexplained. Possible explanations may be differences between species and different sensitivities of the methods used, as suggested by Stelzner et al. (36) .
Possible mechanisms to explain an increase in capillary permeability in AMS/HAPE would be an acute inflammatory reaction and/or oxidant injury. The data we obtained, however, do not support either of these as playing a causative role in AMS or HAPE. First, the plasma concentrations of the proinflammatory cytokines IL-1b and IL-2 did not increase in either group of subjects. However, we cannot rule out that early changes may have occurred that cannot be detected by a global measurement of the plasma concentrations. The increase in plasma concentrations of IL-6 and CRP in the subjects with HAPE occurred after the onset of HAPE (Fig. 4) , suggesting that these were not causative in the development of HAPE. The observation with regard to CRP and the development of HAPE confirms similar data obtained from a study carried out previously at the same location (4) . In regard to the possibility of a free radical-mediated injury to the lung, we had considered a hypothesis whereby a release of TNF might induce an oxidant injury to the lung. However, we did not find any increase in the plasma concentration of F 2 -isoprostanes, nor was there any correlation between the plasma concentration of TNF and the occurrence of AMS or HAPE. As a group, higher levels of TNF were actually found in the subjects who did not experience either AMS or HAPE, primarily because of unusually sustained high levels in two individuals. However, compared with the initial baseline values measured, no significant increases were found at the later time points in any of the groups.
On the surface, our findings may seem inconsistent with the findings of Schoene and colleagues (34, 35) , who reported cellular infiltration, i.e., macrophages and high levels of high-molecular proteins, and inflammatory mediators, e.g., leukotriene B 4 , in the bronchoalveolar lavage fluid of subjects suffering from HAPE. However, because of the design of that study, those data appear to have been obtained during more severe and advanced stages of HAPE. Therefore, the inflammatory reaction may have been a consequence rather than a cause of HAPE.
In summary, exposure to high altitude, irrespective of AMS, does not cause a significant systemic capillary leak. However, we cannot exclude minute changes in systemic or even moderate increases in local pulmonary capillary permeability because the measurement of TER by injecting 125 I-labeled albumin may not reflect organ-specific capillary permeability. Moreover, a solid conclusion in regard to HAPE cannot be drawn from our data because of the small number of subjects with HAPE. The observed increases in the plasma concentrations of inflammatory reactants, at the time point when some subjects had already developed HAPE, suggest that this may be a consequence rather than a cause of HAPE. Collectively, however, our data do not support the notion that exposure to high altitude causes a major alteration in capillary permeability. Rather, results from this and previous studies (5, 15, 29, 33) suggest that altered pulmonary hemodynamics is likely the primary causative factor involved in the pathogenesis of AMS/HAPE.
